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Abstract 
The effect of a superinfection with bluetongue virus serotype 1 (BTV1) was evaluated on two groups of four calves. 
One group received a commercial inactivated BTV serotype 8 (BTV8) vaccine. This group and the non-vaccinated 
group of calves were challenged twice (4 months apart) with the European BTV8 strain isolated during the 2006–2007 
epidemics. Calves were then infected with a BTV1 inoculum which was found to be unexpectedly contaminated 
by BTV serotype 15 (BTV15). BTV1 and BTV15 single infections were performed on two other groups of three BTV 
naïve calves. A severe clinical picture was obtained after superinfection with BTV1/BTV15 in both vaccinated and 
non-vaccinated animals and after challenge with BTV8 in non-vaccinated animals. BTV1 and BTV15 single infection 
caused only very slight clinical signs. After superinfection and at the viraemic peak, there were an average of above 
1000 times more BTV15 genomic copies than BTV1 ones. BTV1 RNA could be detected only in the spleen of one calf 
whereas BTV15 RNA was found in 15 organs of seven different animals. BTV8 immunization whether it was acquired 
through vaccination and challenges or challenges alone did not change BTV1 or BTV15 RNA detection in superin-
fected animals. However in these animals a partial cross neutralization between BTV8 and BTV1 might be involved 
in the lower BTV1 replication versus BTV15. Infection with different serotypes can occur also in the field. Interference 
between virus strains, genetic reassortment and cross-protection were considered as mechanisms to explain the clini-
cal outcomes and the other virological and immunological findings in the course of BTV1/BTV15 superinfection.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Bluetongue (BT) is a non-contagious disease affecting 
ruminants and is caused by the bluetongue virus (BTV), 
the type species of the genus Orbivirus. BT is a World 
Organization for Animal Health reportable disease and 
is of considerable socioeconomic concern and of major 
importance in the international trade of animals and ani-
mal products [1]. Economic losses associated with BTV 
infection are caused directly through reductions in ani-
mal productivity and death, implementation of control 
measures, and more importantly, indirectly through 
trade losses due to animal movement restrictions [2].
Within each different Orbivirus species, several virus 
serotypes are identified, based on the specificity of reac-
tions with the neutralizing antibodies generated by their 
mammalian host [3]. These reactions are dependent to a 
large extent to VP2 and also VP5, which are the most var-
iable proteins in BTV; VP2 especially contains the most 
epitopes that drive neutralizing antibodies production 
and therefore is the main determinant of the serotype 
[4]. To date, 27 serotypes have been identified, including 
BTV25 identified in Switzerland in 2007 [5], BTV26 from 
Kuwait in 2010 [4] and BTV27 detected in goats in Cor-
sica (France) in 2014 [6]. In addition, two putative new 
serotypes, respectively BTV28 and BTV29 were recently 
detected [7]. Indeed serological cross-reactions between 
different serotypes are described [8] and evidences of 
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possible heterologous cross-protection do exist [9, 10], 
but their influence on the epidemiology of the disease is 
not sufficiently understood.
From 2006 to 2015, seven BTV serotypes were detected 
in Western and Central Europe, namely BTV1, 6, 8, 11, 
14, 25, and 27. Most of the economic losses have to be 
attributed to BTV8, and to a lesser extent, BTV1, with 
respectively over 27  000 and 6000 holdings affected 
only in 2008. BTV8 alone was responsible for the death 
of more than 20  000 sheep in Belgium, which repre-
sents 5–10% of the national flock [11]. The 2008 BTV8 
epizootic in Northern Europe is believed to have caused 
greater economic damage than any previous single sero-
type BT outbreak [12]. By contrast re-emergence of 
BTV8 in France in 2015 was only of limited impact [13].
On the other hand, BTV1 that circulated contemporar-
ily in Southwest Europe, was described as a virus leading 
to subclinical or mild disease in cattle [14]. As a conse-
quence of this epidemiologic context, domestic rumi-
nants in the field could be sequentially infected by these 
two serotypes, as it was reported in France and Spain 
[15].
In this paper the results of a 9 month-long experiment 
are shown. Calves were originally divided in two groups, 
with one group being vaccinated against BTV8, and were 
subsequently both challenged with a homologous BTV8 
European strain. In order to mimic the occurrence of 
repetitive infections according to studies reporting sev-
eral peaks of vector activity during the course of the 
year [16], the same calves were infected a second time 
with the same BTV8 strain and later with BTV serotype 
1 (BTV1) (superinfection). The aim of this study was to 
analyse the outcome of these successive challenges, tak-
ing into account the influence of vaccine immunity as 
well as natural post-infection immunity. The BTV1 inoc-
ulum appeared to be contaminated with BTV15 [17]. In 
order to evaluate any in  vivo cross-protection, the con-
sequences of a BTV1 and BTV15 single infection in BTV 
naïve calves were also considered.
Materials and methods
BTV8 successive infections
Ten Holstein female calves, about 6–7  months old, 
were used. All the animals were tested seronegative and 
non viraemic for BTV and bovine viral diarrhoea virus 
(BVDV), and seronegative for bovine herpesvirus 1 
(BoHV1). A thorough general clinical examination was 
carried out on all the animals by a veterinarian before 
including them in the study, to confirm their asympto-
matic state, in accordance to physiological standards [18].
The calves were housed in an insect-secured BSL3 zone 
at the Experimental Infectiology Platform (PFIE) of the 
INRA centre of Tours (Nouzilly, France). The local ethical 
committee approved the experimental protocol (dos-
sier n.2011-10-1). Three groups were created: a group 
of four non-vaccinated calves (group NV, calves 1–4), a 
group with four vaccinated calves (group V, calves 5–8), 
and an environmental control group with two calves 
(group C, calves 15 and 16). Vaccination against BTV8 
was performed using the inactivated commercial vaccine 
BTVPUR AlSAP 8 (Merial, Lyon, France) following man-
ufacturer’s instructions.
Calves of group V and NV were infected twice, 
4  months apart, using the same BTV8 inoculum 
described in a previous experimental infection [19]. 
Briefly, a calf inoculated with a BTV-8 strain passaged 
twice in baby hamster kidney fibroblasts (BHK-21) cells 
(BEL2006/01 BHK-21 P2), was blood sampled at the 
viraemic peak, showing clinical signs. The first infection 
took place 50 days after the second vaccine shot, and the 
second challenge 120  days later (Figure  1A). Each time, 
half of the dose was inoculated via the jugular vein and 
half subcutaneously. For each one of these challenges, all 
eight infected animals were administered a total of 15 mL 
of blood, corresponding to a titre of 103 embryo lethal 
dose 50 (ELD50).
The animals were daily examined and sampled for 
EDTA-blood and whole blood on dry tubes during the 3 
first weeks after infection, then twice a week until super-
infection. For clarification purpose, days post infection 
regarding BTV8 successive infection are mentioned as 
dpiBTV8, with day of first challenge as dpiBTV8 0.
BTV superinfection
About 5  months (160  days) after the first BTV8 infec-
tion, and 40 days after the second one, calves of groups 
NV and V were challenged with BTV1 infectious blood, 
kindly provided by the Friedrich-Loeffler Institute. Each 
animal received 106.15 tissue culture infective dose 50% 
(TCID50) of virus, half intravenously and half subcutane-
ously. An incidental contamination of the inoculum with 
BTV15 was discovered during the course of the study 
[17].
The animals were daily examined and sampled for 
EDTA-blood and whole blood on dry tubes until the end 
of the experiment.
Calves were euthanized 21  days after the superinfec-
tion and necropsied (Figures 1A and B). Days post infec-
tion for superinfection is mentioned as dpiBTV1/15.
BTV1 and BTV15 single infections
Eight Holstein male calves, about 6–7 months old, were 
housed in the BSL3 facility, at CODA-CERVA’s (Vet-
erinary and Agrochemical Research Centre, Uccle, Bel-
gium) experimental centre (Machelen, Belgium). These 
animals fulfilled the same inclusion criteria of the BTV8 
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successive infections and were naïve for BTV, BVDV and 
BoHV-1. The experimental protocol was reviewed by the 
competent authority (Ethical Committee of the Institute 
of Public Health-Veterinary and Agronomical Research 
Centre) and subsequently approved (ref. 110228-01 RT 
10/10 BLUETONGUE).
After an acclimatization period of 2 weeks, calves were 
divided in three groups [BTV1: calves 9–11, and BTV15: 
calves 12–14, single infections; mock-infection: four 
calves (calves 17–20)]. The infection was performed with 
a volume of 1 mL of virus diluted in Dulbecco’s modified 
eagle medium (DMEM, Lonza BioResearch, Belgium), 
half intravenously and half subcutaneously.
The BTV1 strain has been provided by CODA-CERVA, 
from sub-saharian origin, derived from the European 
Community Reference Laboratory for bluetongue at the 
Pirbright Laboratory, UK collections, and subsequently 
passaged two times in BHK-21 cells. The infection was 
performed with 106 TCID50 per animal.
BTV15 was provided by CODA-CERVA, derived from 
the European Community Reference Laboratory for blue-
tongue at the Pirbright Laboratory, UK and was then pas-
saged twice on BHK21 cells at CODA-CERVA. Calves 
were infected with 104 TCID50.
Mock-infected calves were inoculated with sterile 
DMEM following the same routes and volume.
The animals were daily examined and sampled for 
EDTA-blood and whole blood on dry tubes until the end 
of the experiment. Calves were euthanized 35 dpi and 
necropsied. Days post infection for single infections are 
mentioned as dpisingle.
Clinical and post‑mortem examination
After each challenge, the individual body temperature 
and the clinical signs were monitored for 3  weeks. The 
severity of the infection was quantified by calculating 
clinical scores on a daily basis, leading to overall cumu-
lative clinical scores by groups and animal. For this 
Figure 1 Neutralising antibodies and viral RNA detection following BTV8 challenges and BTV1/BTV15 superinfection. A Mean 
neutralising antibodies titres and mean copy number of VP2 cDNA are shown for vaccinated (V) and non-vaccinated (NV) calves, after vaccinations 
and challenges with BTV8 and BTV1/BTV15 superinfection. Standard deviation is shown as error bars. The two vaccine injections are represented as 
arrows followed by Vacc1 and Vacc2 respectively. Infectious challenges are represented as arrow labelled with the corresponding serotypes. * above 
braces: time period with neutralising Abs titre of V group significantly higher than NV group; P < 0.05. B Focus on the BTV1/BTV15 superinfection 
experiment.
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purpose, a standardised clinical form adapted from Sae-
german et al. was used [20]. As BTV1 and BTV15 single 
infections only involved three animals whereas other 
groups had four calves each, total clinical score was pon-
dered to allow direct comparison of clinical scores from 
different experiments.
Samples of spleen, thymus, prescapular and mesenteric 
lymph nodes were collected from infected and control 
calves and stored at −80 °C for virus detection.
Serology
Neutralizing antibodies (Abs) were titrated by seroneu-
tralization (SNT). Two-fold serial dilutions of the sera 
(1:10–1:1280) were tested in the presence of 100 TCID50 
of virus, as previously described [21]. The neutralizing 
antibody titre was defined as the reciprocal of the serum 
dilution causing a 50% reduction in cytopathic effect. 
Serum samples with a titre <20, =20 and >20 were con-
sidered negative, doubtful and positive, respectively.
In order to identify in  vitro cross neutralization 
between BTV1, BTV8 and BTV15, the serum of the calf 
infected with BTV8 and showing the highest anti-BTV8 
antibody titre was tested in the presence of BTV1 or 
BTV15. Similarly, the serum of the calves infected with 
BTV1 and BTV15 following single serotype infections 
and showing the highest neutralizing antibody titres 
against the correspondent virus were tested against 
heterologous serotypes. In  vitro cross neutralization 
was measured using the percentage of neutralization 
obtained using heterologous serotypes with immune 
serum and compared to homologous neutralization as 
reference (100%).
In the course of the two BTV8 challenges, and after 
BTV1 and BTV15 single infections, seroconversion 
against VP7 antibodies was also evaluated using a com-
mercial competitive ELISA kit (ID Screen® Bluetongue 
Competition ELISA kit, ID Vet, France). Results were 
expressed as % of negativity (PN) compared to the nega-
tive kit control and transferred to a positive, doubtful or 
negative result according to the cut-off settings provided 
by the manufacturer (PN ≤ 35 is positive; 35 < PN ≤ 45 is 
doubtful; PN > 45 is negative).
BTV RNA detection
Viral RNA extraction from the blood was achieved 
using the QIAamp Viral RNA Mini Kit (Qiagen, Ger-
many). Viral RNA denaturation and reverse transcrip-
tion followed by qPCR were performed as previously 
described [22]. BTV RNA was detected by serotype spe-
cific RTqPCR, using a fragment of BTV segment 2 as the 
target. Serial dilutions of in  vitro constructed plasmids 
(pGEM®-T Easy Vector, Promega, The Netherlands) car-
rying the target part of the segment 2, specific for each 
serotype, allowed the absolute quantification of the 
viral cDNA equivalent in samples. Quantification was 
expressed in cDNA copy number/mL of blood. RTqPCR 
cycling conditions, primers and probes were similar 
to the ones described by Vandenbussche et  al. [22] for 
BTV1 and BTV8 (RTqPCR_BTV1_S2 and RTqPCR_
BTV8_S2, respectively), and Eschbaumer et  al. [18] for 
BTV15 (RTqPCR_BTV15_S2). In all the RTqPCR of this 
study, bovine beta-actin was contemporaneously ampli-
fied as internal control (RTqPCR_ACT) [23].
BTV RNA detection was performed on all the collected 
organs starting from approximately 100  mg of tissue, 
which was processed using TRI reagent according to the 
manufacturer’s instructions (Life Technologies Europe 
BV, Gent, Belgium). BTV and bovine beta-actin detec-
tion were performed by RTqPCR as described above.
Viral growth assay
In vitro replication of BTV1, BTV8 and BTV15 were com-
pared on VERO and Bovine Pulmonary Endothelial cells 
(BPAEC). BTV8 was the same as in the BTV8 successive 
infections, and BTV1 and BTV15 were the same as in sin-
gle infections. These viruses were used for a growth assay 
following a protocol previously described [24]. Briefly, 
VERO and BPAEC confluent cells in 24 wells plates were 
inoculated with a multiplicity of infection (M.O.I.) of 0.05, 
and after 0, 8, 24, 48 and 120 h post infection (hpi), super-
natant was removed and stored at −80  °C. Each virus 
underwent three independent assays on each cell type. 
Supernatants were then titrated by end-point dilution and 
titres expressed as Log10 of TCID50/mL.
Statistical analysis
Mean cumulative clinical scores were analysed using 
linear mixed model, with calf as random effect. Virae-
mia and serological results were compared using two-
way ANOVA with repeated measures. RNA detection 
in organs at necropsy, frequencies and proportions were 
compared with Fisher’s Exact Test for count data [25]. 
For all tests, P values <0.05 were considered significant. 
In case of multiple comparisons, a Bonferroni correction 
was applied to reduce the risk of type I error (conserva-
tive approach) and a Holm correction was applied when 
more than four comparisons had to be tested. Statistical 
analyses were performed using the R software/environ-
ment (R-3.1.2, R Foundation for Statistical Computing, 
[26]) and SAS software, Version 9.3 TS level 1M2 of the 
SAS System for Unix, and SAS University Edition (SAS 
Institute, Cary, NC, USA).




From the beginning to the end of the experiment, control 
calves and vaccinated animals (V) did not show any clini-
cal signs that could be related to BTV infection. After 
the first challenge, clinical signs showed by NV calves 
were slight, mostly consisting in ocular lesions and to a 
lesser extent by oral lesions. Clinical signs consistent with 
BTV8 infection could be reported from 7 to 21 dpiBTV8. 
After the second challenge no clinical manifestations or 
temperature rise could be detected in any animal.
Serology
VP7 and anti-BTV8 neutralizing Abs in control calves 
could not be detected at any tested time points.
First vaccination of the calves did not induce detectable 
neutralizing Abs, which could only be detected 7  days 
after the booster vaccination. In NV group, neutralizing 
Abs were first detected at 18  dpiBTV8 (Figure  1A). The 
titre of anti-BTV8 neutralizing Abs of the V group was 
significantly higher between −43 dpiBTV8 (thus 35  days 
after the first vaccine shot) and 27  dpiBTV8 (P  <  0.005), 
and then Abs titres of both NV and V groups followed a 
similar trend until the end of the experiment (Figure 1A).
Following the second BTV8 challenge, neutralizing Abs 
titres underwent a boost in both NV and V groups until 
33 dpiBTV8 (Figure 1A).
The use of an ELISA allowed the detection of anti-VP7 
Abs in all the vaccinated animals as soon as 3 days after 
second vaccine injection (Figure  2). Then PN of vacci-
nated animals did not evolve significantly until the end 
of the measures at 180  dpiBTV8 (Additional file  1). Non-
vaccinated calves were confirmed seropositive between 10 
and 19 dpiBTV8, with no significant variations until the end 
of the measures at 180 dpiBTV8 (Additional file 1, P > 0.05).
BTV RNA detection
BTV8 RNA was never detected in the EDTA-blood samples 
of control and vaccinated calves during the course of the two 
BTV8 infections. In the NV group of calves, BTV RNA could 
be detected starting from 5 dpiBTV8. After the viraemic peak 
(11–15 dpiBTV8) a progressive decrease in BTV8 RNA was 
measured (Figures 1A and B), until the end of the experiment.
BTV superinfection
Clinical and post‑mortem examination
In the NV as well as in the V group, lesions following 
BTV1/BTV15 superinfection were mainly conjunctivitis 
Figure 2 Serology, RNA detection and cross neutralization 
results following single infections with BTV1, BTV15 and 
BTV8. A Results of RTqPCR and SNT in V and NV groups of calves, 
after BTV1 and BTV15 single infection challenges compared with 
BTV8 first challenge in NV group. Dashed lines represent SNT results. 
B cELISA % of negativity following BTV1 and BTV15 single infection, 
BTV8 vaccination in V group and first BTV8 challenge in NV group. 
Dotted line represents positivity threshold, with % of negativity <35 
considered as positive. C Cross neutralization results, with BTV1, BTV8 
and BTV15 compared to the respective heterologous immune serum. 
Results are expressed as a percentage of the highest homologous 
neutralization titre. *P < 0.05; **P < 0.01.
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with serous to purulent discharge. Erosions of the muz-
zle, erosions and ulcerations of the gums and the dental 
pad and later crusts on the muffle or on the cutaneous-
mucous junction were commonly notified. Reddening 
and swelling of the coronal margin and interdigital space 
were also mentioned. Conjunctivitis and congestion of 
the lower limb were mild to severe and respectively less 
severe and absent in the previous BTV8 infection. At the 
end of the experiment cumulative clinical score of the 
NV BTV1/BTV15 superinfected group was higher than 
in NV BTV8 and V BTV1/BTV15 groups, however the 
difference was not significant (P > 0.4, Additional file 2).
The necropsy revealed petechial haemorrhages of lim-
ited extent in prescapular and submandibular lymph 
nodes, and thymus, at least in one of these organs in all 
the superinfected calves. BTV8 RNA could be detected 
in prescapular lymph node of one calf and in the spleen 
of another one, both from NV group; BTV1 RNA could 
only be detected in the spleen of one vaccinated calf and 
BTV15 RNA could be detected with a significant higher 
frequency (P < 10−5) in 15 organs belonging to 7 different 
calves (5/15 in NV group and 10/15 in V group; Figure 3).
No BTV RNA could be detected in any of the tested 
organs from control animals.
Serology
After the superinfection, high levels of residual neutral-
izing antibodies against BTV8 were found throughout 
the experiment in all the infected animals, with a roughly 
steady level (Figures  1A  and B). There were no signifi-
cant differences between NV and V groups through time 
in anti BTV8 neutralizing antibodies (two-way ANOVA 
with repeated measures, group effect: P  =  0.78, group 
time interaction: P = 0.84). By contrast, BTV1 only gave 
rise to very low titres of neutralizing antibodies.
BTV15 neutralizing antibody titre increased regularly 
after infection, with a positive titre detectable in most of 
the animals at 9  dpiBTV1/15 (Figure  1B). BTV15 neutral-
izing Abs followed an increasing trend until the time of 
euthanasia; in previously vaccinated animals a higher 
and significant earlier raise of neutralizing antibody 
was found compared to non-vaccinated ones (two-way 
ANOVA with repeated measures, group effect: P < 0.02, 
group time interaction: P < 2 × 10−4) (Figure 1B).
BTV RNA detection
At the time of the superinfection, a residual BTV8 RNAe-
mia was detected in the NV group of calves. BTV8 
RNAemia decreased through the time of the experi-
ment, but was still detectable in all the NV animals by 
the time of euthanasia (180  days after the first BTV8 
challenge—Figure 1).
The superinfection inoculum contained respectively 
106.8 and 107.6 copies of segment 2 cDNA per mL of 
blood, for BTV1 and BTV15.
After superinfection in the NV and the V groups, 
BTV1 could only be detected inconstantly, from one to 
3  days amongst all the tested day-points and at lower 
Figure 3 BTV RNA detection in organs. A BTV1, BTV8 and BTV15 detection in organs following BTV1/BTV15 superinfection. B BTV1 and BTV15 
detection in organs following single infections. Results are expressed as Log10 copy number/100 mg of tissue. Mesent. LN: Mesenteric lymph node. 
Prescap. LN: Prescapular lymph node.
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copy number than BTV15 (Figure 1B). On the contrary, 
BTV15 could be easily detected in both groups and 
among all the infected calves. RNAemia through time 
was significantly different between BTV15 and BTV1 
whichever the considered vaccination status of the ani-
mals (P  <  10−8). Mean copy number at viraemic peak 
was 105.4 (±0.7 Log) cDNA copy number/mL of blood 
for BTV15 and 102.4 (±1.8 Log) for BTV1. BTV15 could 
be detected until the end of the experiment (Figure 1B). 
Between V and NV groups, detection of BTV1 and 
BTV15 was not significantly different (P  =  0.18 and 
P = 0.86 for BTV1 and BTV15 respectively).
No viral RNA could be detected in control animals 
(data not shown).
BTV1 and BTV15 single infections
Clinical and post‑mortem examination
During BTV1 single infection, one calf underwent spo-
radic hyperthermia and all the three calves of the group 
had mild oral and ocular lesions. No systemic impact was 
reported in any of these animals.
During BTV15 single infection, infected animals 
showed very mild clinical conditions compatible with BT, 
including congestion and crusts on the nostrils and oral 
mucosa. One calf showed hyperthermia at 7 dpi (39.6 °C) 
and at 14 (40  °C) and 15 dpi (40.7  °C), with no other 
lesion throughout the experiment (Additional file 2). No 
hyperthermia was recorded in any of the other cattle at 
any stage of the experiment.
Overall, the sum of clinical scores in BTV1 and BTV15 
single infected groups were not significantly different 
when compared to control animals or to the V group 
after BTV8 challenge (P  >  0.14), but were significantly 
lower when compared to first BTV8 challenge in NV 
calves and the superinfection with BTV1/15 inoculum in 
both V and NV groups (P < 0.002).
Necropsy for BTV1 single infection revealed moderate 
petechial haemorrhages in mesenteric and mediastinic 
lymph nodes in one calf, prescapular and mediastinic 
lymph nodes in another one and no lesions in the last 
one.
In the calves with BTV15 single infection, no BTV 
specific lesions could be found at necropsy. Petechial 
haemorrhages were reported on the thymus and the 
prescapular lymph node of two calves, respectively, in 
both cases on a limited amount.
All the three BTV1 infected calves had a positive BTV1 
detection in prescapular lymph nodes. In addition, viral 
RNA could be detected in the thymus and spleen of two 
other calves, respectively (Figure 3).
RTqPCR revealed BTV15 positive detection in the 
spleen and the prescapular lymph nodes of all of the 
three BTV15 infected calves. In addition, thymus and 
mesenteric lymph node were shown to be positive in 
two calves, respectively (Figure  3). The frequency of 
positive detection in organs was not different between 
BTV1 and BTV15 (Fisher’s Exact Test for count data, 
P > 0.4).
No specific lesions or BTV RNA detection could be 
found in control animals. A few non-specific abscesses 
could be found in the lung of one of these calves.
Serology
During BTV1 single infection anti-BTV1 neutraliz-
ing antibodies could be detected for the first time at the 
16 dpisingle tested time point and then increased regularly 
until the end of the experiment (Figure  2A). Similarly, 
also anti-BTV15 neutralizing antibodies were measured 
starting from 16 dpisingle in the course of BTV15 single 
infection and the titres increased regularly until the time 
of euthanasia (Figure 2A).
There was no significant difference between SNT titres 
of BTV1 and BTV15 single infection and BTV8 after first 
infection in NV group during the first 35 days (P > 0.24).
BTV1 infected calves seroconverted regarding anti-
VP7 antibodies between 7 and 16 dpisingle, and were still 
all seropositive at the end of the experiment.
Anti-VP7 Abs in BTV15 infected animals clearly 
increased between 10 and 15 dpisingle in all infected calves 
(Figure  2B). However, only 1/3 calves seroconverted 
at the end of the experiment at 35 dpisingle, whereas the 
two other calves remained slightly out the positivity limit 
(mean PN =  38 ±  5.7, Figure  2B). At 35  dpisingle PN of 
BTV15 infected group was significantly higher when 
compared to BTV1 single infection group and BTV8 
groups at 35 dpiBTV8 (P < 0.007).
In vitro cross neutralization assay only showed lim-
ited cross reactivity between BTV8 immune serum 
against BTV1 virus (18%  ±  7.4% of the BTV8 immune 
serum homologous neutralization, Figure 2C). However, 
this cross reactivity was significantly higher than the 
one measured between BTV1 versus BTV15 immune 
serum, BTV8 versus BTV1 and BTV15 immune serums 
(P  <  0.02). BTV1 and BTV8 immune serum elicited a 
limited cross reactivity toward BTV15 (10% ± 4.5% and 
10% ± 1.8%, respectively).
BTV RNA detection
In the course of BTV1 single infection BTV RNA could 
be detected as soon as 1 dpi in all the calves of the group, 
but then could only be detected again at 2 and 3 dpi for 
respectively one and two calves.
During BTV15 single infection viral RNA could be 
detected starting from 7  dpi in all three calves. BTV15 
RNA could be detected until the end of the experiment 
(Figure  2A). The levels of RNA peaked in the blood of 
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both BTV1 and BTV15 groups between 9 and 11 dpisin-
gle. BTV1 cDNA copy number detected in single infected 
calves was significantly higher than in BTV1 superin-
fected ones, no matter their vaccination status (P < 10−4). 
By contrast, there were no significant differences in cDNA 
copy numbers between BTV15 superinfected (V and NV 
groups), BTV1 and BTV15 single infected calves (P > 0.2). 
Moreover, BTV1 and BTV15 cDNA copy numbers were 
not significantly different from BTV8 cDNA copy number 
during first infection in NV group (P > 0.13).
Viral growth assay
From 0 to 24–48 hpi, BTV1 showed a faster replication, 
however not significant, whichever the considered cell 
line (Figure 4). In VERO cells BTV15 grew less efficiently 
than BTV1 from 0 to 48  hpi (P  <  10−5), but finally 
reached by 120 hpi similar titres to BTV1 and BTV8 in 
VERO cells (P > 0.14) and to BTV1 in BPAEC (P > 0.9). 
Homologous viral growth was not significantly different 
between cell types (P =  0.15), and there was no signifi-
cant differences between serotypes in BPAEC (P > 0.3).
Discussion
The influence of the existent active immunity towards 
the European BTV8 strain on the outcomes of a super-
infection with BTV1 was evaluated. The BTV1 inoculum 
appeared to be contaminated with BTV15 thus the ani-
mals were actually infected with a mixed BTV1–BTV15 
inoculum. BTV8 active immunity was evaluated either by 
vaccination followed by infectious challenges or by infec-
tious challenges alone. Two successive infections with 
the same BTV8 strain were realized 4  months apart. In 
line with field data [9], vaccination only elicited the pro-
duction of neutralizing Abs detectable after the second 
vaccine boost. Vaccinated animals underwent a signifi-
cantly earlier detection of neutralizing antibodies after 
the first BTV8 challenge when compared to non-vac-
cinated calves. In the NV BTV8 group, the detection of 
BTV8 RNA lasted until 180 dpiBTV8 (end of the experi-
ment), which is consistent with currently existing litera-
ture data [27, 28]. Non-vaccinated calves infected with 
BTV8 showed a slight to mild clinical picture. A moder-
ate impact of the disease caused by BTV8 on cattle is not 
unusual, in experimental infections [22, 29] as well as in 
the field [30–32].
After the unexpected contamination of the BTV1 
inoculum with BTV15, the influence of both viruses on 
the outcome of the infection was investigated. In the 
inoculum used for the superinfection, the copy num-
ber of BTV1 segment 2 cDNA per mL of inoculum was 
about tenfold lower than BTV15. After superinfection 
BTV1 could be found irregularly and only at a few tested 
time-points in the blood of the calves while BTV15 was 
detected with high levels of RNAemia until the end of the 
experiment in both V and NV groups. The overwhelming 
replication of BTV15 versus BTV1 is in line with results 
reported by Eschbaumer et  al. [18]. Domination of one 
serotype on another during mixed infection has been 
previously reported [33] and the same authors observed 
that about 5% of progeny viruses were actually reassor-
tants. Any genome segment can be involved in reassort-
ment which is readily generated, as demonstrated by 
Shaw et  al. [34]. As in the current study viral RNA was 
based on segment 2 quantification, it is not possible to 
rule out that some of the segment 2 detected by RTqPCR 
being actually part of reassortant viruses. This was also 
one of the hypotheses brought to light by Dal Pozzo et al. 
[25] to explain the predominance of BTV8 on BTV1 and 
Figure 4 In vitro growth kinetics of BTV1, 8 and 15 on VERO 
and BPAEC cells. VERO cells (A) and BPAEC (B) were infected at a 
multiplicity of infection (M.O.I.) of 0.05 and supernatants collected 
at 8, 24, 48, and 120 h post infection (hpi). Viruses were the same as 
used for single infection (BTV1 and BTV15) and BTV8 was the same 
as in the BTV8 successive infection experiment. Supernatants were 
then titrated on VERO cells by end-point dilution and the virus titres 
expressed as log10 TCID50/mL. Three different assays were performed 
independently, each time involving the three serotypes, tested on the 
different cell lines. Standard deviations are displayed as error bars.
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BTV15 in the course of a triple co-infection. Another 
possible explanation is the viral interference, occurring 
between two or more viruses infecting simultaneously 
the same host.
BTV8 was recently used to study underlying IFN-I con-
trol mechanisms by the virus [35]. To investigate whether 
the different tested serotypes would also show different 
replication patterns in  vitro or not, growth curves of 
BTV1, BTV8 and BTV15 were established in two com-
mon cell lines, BPAEC and VERO cells. VERO cells are 
deficient for IFN-I production [36]. BTV15 did not repli-
cate as much as BTV1 in VERO cells during the first 48 h. 
Nevertheless, in IFN-I competent cells such as BPAEC 
primary line, both BTV serotypes replicated follow-
ing a similar pattern through time. These results are not 
inconsistent with the hypothesis of BTV15 to be better 
adapted to IFN-induced state when compared to BTV1, 
possibly explaining the relatively more efficient rep-
lication of BTV15 in  vivo or in  vitro in IFN-competent 
cell lines. Another hypothesis to explain the difference 
between BTV1 and BTV15 RNAemia after superinfec-
tion might be related to the influence of BTV8 immu-
nity on these two serotypes. The level of heterologous 
reactivity as assessed by SNT between BTV8 immune 
serum and BTV serotypes 1 and 15 was low, yet higher 
for BTV1 (18  ±  7.4% versus 10  ±  1.8% for BTV1 and 
BTV15, respectively; Figure  2C). This result is in line 
with Hund et  al., which reported partial cross neutrali-
zation between BTV8 positive serum and BTV1, despite 
the genetic distance between these serotypes [9].
In addition, no significant difference was reported 
between RNAemia of BTV15 superinfected calves (from 
V and NV groups, both immunized against BTV8) and 
RNAemia of BTV15 single infected calves. Thus this low 
in vitro humoral cross reactivity between BTV8 immune 
serum and BTV15 seemed to have no significant influ-
ence on BTV15 RNAemia in vivo in contrast to the BTV1 
RNAemia.
BTV1/BTV15 superinfection led to clinical disease in 
both V and NV animals. On the contrary, during BTV1 
and BTV15 single infection the calves had very low clini-
cal scores. The reason of this difference remains uncer-
tain; however individual variability could be part of the 
explanation.
After superinfection, BTV1 neutralizing Abs only 
reached very low levels, as a consequence of the very 
low BTV1 RNA detection. By contrast, BTV15 neutral-
izing Abs extended to high titres, either in BTV1/BTV15 
superinfected animals or in BTV15 single serotype 
infected calves.
Despite high neutralizing Abs detection following 
BTV15 single serotype infection, ELISA detecting VP7 
Abs showed a mean PN at 35 dpi just above the positivity 
threshold. This is consistent with previous reports show-
ing that significant immunological differences exist 
between BTV15 and other BTV serotypes and that mon-
oclonal antibodies raised against BTV1 VP7 failed to 
react with BTV15 VP7 [37]. When assessing diagnostic 
tools aiming at non-serotype specific detection, it would 
be therefore advisable to include distantly related strains 
in the test panel to cover most of the genetic variability 
displayed by BTV proteins.
Vandenbussche et  al. suggested to use the ID Vet 
cELISA kit with a cut off of 66 PN instead of 35 for BTV8, 
as recommended by the manufacturer, to achieve optimal 
accuracy for both screening and diagnostic [38]. Taking 
into account this suggestion, all of the three calves would 
have been considered as seropositive by day 21 post 
infection with BTV15.
Unlike the European BTV8, known for its increased 
virulence in bovine, BTV1 and BTV15 have been associ-
ated with subclinical or very mild disease in this species. 
Numerous factors are known to influence the severity of 
BT in individual ruminants; nutritional status, immune 
status and age, breed, environmental stresses such as 
high temperature and ultraviolet radiation [39]. In this 
study, the accidental co-infection with BTV1 and BTV15 
and the obtained severe clinical outcome underlined the 
potential higher pathogenicity of a co-infection.
The main objective of this study was to observe the 
outcomes of a superinfection in calves previously immu-
nized with the European BTV8. BTV1 or BTV15 RNA 
detection in superinfected animals was not different 
whether BTV8 immunization was acquired through vac-
cination and challenges or challenges alone. Furthermore, 
a low cross neutralization was measured between BTV8 
and BTV1, and between BTV8 and BTV15. Taken all 
together in the context of the European BT epidemiologi-
cal situation, the results could suggest that an infection or 
a vaccination with the European BTV8 strain would not 
efficiently protect the bovines from a superinfection with 
the BTV1 or BTV15 strains used in the study.
Additional files
Additional file 1.  BTV group specific anti-VP7 antibodies, after 
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represented as error bars.
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tion and BTV1 and BTV15 single infections. Sd: Standard deviation.
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